ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 532,34
0,39%
Dow Jones
38 589,16
0,00%
DAX
18 038,93
0,10%
Brent Oil
82,545
0,51%
Bitcoin
65 633,37
-1,51%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. InflaRx NV (IFRX)

  7. InflaRx NV (IFRX) Actualités

IFRX

InflaRx NV (IFRX)

InflaRx NV
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:IFRX
DateHeureSourceTitreSymboleSociété
05/06/202423h07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
05/06/202418h00GlobeNewswire Inc.InflaRx Hosts R&D Event Highlighting the Promise of INF904NASDAQ:IFRXInflaRx NV
21/05/202420h30GlobeNewswire Inc.InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other ImmunomodulatorsNASDAQ:IFRXInflaRx NV
08/05/202413h30GlobeNewswire Inc.InflaRx Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:IFRXInflaRx NV
30/04/202413h30GlobeNewswire Inc.InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024NASDAQ:IFRXInflaRx NV
24/04/202413h30GlobeNewswire Inc.InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters EventNASDAQ:IFRXInflaRx NV
21/03/202412h00GlobeNewswire Inc.InflaRx Reports Full Year 2023 Results and Announces INF904 Development PlansNASDAQ:IFRXInflaRx NV
19/03/202412h30GlobeNewswire Inc.InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024NASDAQ:IFRXInflaRx NV
22/02/202413h30GlobeNewswire Inc.InflaRx Appoints Jan Medina as Head of Investor RelationsNASDAQ:IFRXInflaRx NV
25/01/202413h30GlobeNewswire Inc.InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible PatientsNASDAQ:IFRXInflaRx NV
04/01/202413h00GlobeNewswire Inc.InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904NASDAQ:IFRXInflaRx NV
06/11/202313h30GlobeNewswire Inc.InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma GangrenosumNASDAQ:IFRXInflaRx NV
01/11/202312h30GlobeNewswire Inc.InflaRx Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:IFRXInflaRx NV
11/09/202313h00GlobeNewswire Inc.InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904NASDAQ:IFRXInflaRx NV
30/08/202313h30GlobeNewswire Inc.InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)NASDAQ:IFRXInflaRx NV
10/08/202313h30GlobeNewswire Inc.InflaRx Reports Second Quarter 2023 Financial Results & Operating UpdateNASDAQ:IFRXInflaRx NV
12/07/202322h01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IFRXInflaRx NV
12/07/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IFRXInflaRx NV
30/06/202322h06Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:IFRXInflaRx NV
28/06/202314h31Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:IFRXInflaRx NV
28/06/202313h30GlobeNewswire Inc.InflaRx Appoints Dr. Camilla Chong as Chief Medical OfficerNASDAQ:IFRXInflaRx NV
21/06/202313h00GlobeNewswire Inc.InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 PatientsNASDAQ:IFRXInflaRx NV
11/05/202313h30GlobeNewswire Inc.InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business UpdateNASDAQ:IFRXInflaRx NV
24/04/202322h48Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:IFRXInflaRx NV
18/04/202322h01GlobeNewswire Inc.InflaRx Announces Closing of the Full Exercise of Greenshoe Option Increasing the Proceeds of the Recently Announced Public Offering of Ordinary Shares to US$46 millionNASDAQ:IFRXInflaRx NV
14/04/202322h01GlobeNewswire Inc.InflaRx Announces Closing of $40 Million Public Offering of Ordinary SharesNASDAQ:IFRXInflaRx NV
13/04/202314h48Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:IFRXInflaRx NV
12/04/202303h08GlobeNewswire Inc.InflaRx Announces Pricing of $40 Million Public Offering of Ordinary SharesNASDAQ:IFRXInflaRx NV
11/04/202322h00GlobeNewswire Inc.InflaRx Announces Public Offering of Ordinary SharesNASDAQ:IFRXInflaRx NV
05/04/202317h30Dow Jones NewsInflaRx Shares Soar 40% on FDA Emergency Use Authorization of Gohibic for Covid-19NASDAQ:IFRXInflaRx NV
 Showing the most relevant articles for your search:NASDAQ:IFRX

Dernières Valeurs Consultées

ASX
AMPLOB
ASX
STOSO3
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés